NCT02145039

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Reduced Intensity Conditioning (RIC) and Transplantation of HLA(Human Leukocyte Antigen)-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 74 Years
• Healthy volunteers: Not accepted

Summary

This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.

Conditions

• Acute Leukemias
• Burkitt's Lymphoma
• Chronic Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	Fludarabine	Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
DRUG	Cyclophosphamide	Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
RADIATION	Total Body Irradiation	TBI 200cGy on day -1 before transplant.
BIOLOGICAL	Haploidentical stem cell transplant	Non-T-cell depleted bone marrow infusion

Timeline

• Start date: 2014-10-01
• Primary completion: 2018-01-01
• Completion: 2019-01-01
• First posted: 2014-05-22
• Last updated: 2019-12-26
• Results posted: 2019-12-26

Locations

1 site across 1 country: United States